Breaking News Instant updates and real-time market news.

INCY

Incyte

$97.83

3.05 (3.22%)

, MRK

Merck

$62.77

0.11 (0.18%)

08:52
10/10/16
10/10
08:52
10/10/16
08:52

Incyte treatment looking 'promising,' says JMP Securities

After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

INCY

Incyte

$97.83

3.05 (3.22%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 10

    Oct

  • 25

    Oct

  • 06

    Nov

INCY Incyte
$97.83

3.05 (3.22%)

10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
10/07/16
BMOC
10/07/16
NO CHANGE
Target $121
BMOC
Outperform
Incyte price target raised to $121 from $100 at BMO Capital
BMO Capital analyst Ian Somaiya raised his price target for Incyte to $121 citing an increased probability of success for epacadostat with Keytruda in metastatic melanoma following today's data. The analyst raised his probability and success to 80% from 50% and keeps an Outperform rating on Incyte.
MRK Merck
$62.77

0.11 (0.18%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.

TODAY'S FREE FLY STORIES

IPAR

Inter Parfums

$36.95

0.2 (0.54%)

16:33
04/27/17
04/27
16:33
04/27/17
16:33
Earnings
Inter Parfums backs FY17 EPS $1.20-$1.24, consensus $1.25 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MERC

Mercer

$12.55

0.1 (0.80%)

16:33
04/27/17
04/27
16:33
04/27/17
16:33
Earnings
Mercer reports Q1 EPS 15c, consensus 28c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SGMS

Scientific Games

$22.80

-0.1 (-0.44%)

16:33
04/27/17
04/27
16:33
04/27/17
16:33
Earnings
Scientific Games reports Q1 EPS ($1.14), consensus (72c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 30

    May

VDSI

VASCO Data Security

$13.60

-0.05 (-0.37%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
Breaking Earnings news story on VASCO Data Security »

VASCO Data Security sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

IPAR

Inter Parfums

$36.95

0.2 (0.54%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
Inter Parfums reports Q1 revenue $143.1M, consensus $120.19M. »

"The 57% increase in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VDSI

VASCO Data Security

$13.60

-0.05 (-0.37%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
VASCO Data Security reports Q1 non-GAAP EPS 8c, consensus (3c) »

Reports Q1 revenue $42M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

LRN

K12

$20.26

-0.17 (-0.83%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
K12 sees Q4 revenue $215M-$220M, consensus $223.96M »

Sees Q4 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

EHTH

eHealth

$11.74

0.23 (2.00%)

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Earnings
Breaking Earnings news story on eHealth »

eHealth sees FY17 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

  • 30

    May

  • 06

    Jun

BIDU

Baidu

$187.86

1.19 (0.64%)

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Earnings
Baidu sees Q2 revenue $2.974B-$3.048B, consensus $3.03B »

Representing an annual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

LRN

K12

$20.26

-0.17 (-0.83%)

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Earnings
K12 reports Q3 EPS 23c, consensus 25c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Options
Preliminary option volume of 15.6M today »

Preliminary option volume…

EHTH

eHealth

$11.74

0.23 (2.00%)

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Earnings
eHealth sees FY17 revenue $165M-$175M, consensus $169.3M »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

  • 30

    May

  • 06

    Jun

TRMB

Trimble

$32.62

0.28 (0.87%)

16:30
04/27/17
04/27
16:30
04/27/17
16:30
Earnings
Trimble sees Q2 non-GAAP EPS 33c-38c, consensus 34c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

VSAR

Versartis

$19.80

-0.1 (-0.50%)

16:30
04/27/17
04/27
16:30
04/27/17
16:30
Earnings
Breaking Earnings news story on Versartis »

Versartis reports Q1 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIDU

Baidu

$187.86

1.19 (0.64%)

16:30
04/27/17
04/27
16:30
04/27/17
16:30
Earnings
Baidu reports Q1 adjusted EPS $1.00, consensus 86c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

TRMB

Trimble

$32.62

0.28 (0.87%)

16:30
04/27/17
04/27
16:30
04/27/17
16:30
Earnings
Trimble reports Q1 non-GAAP EPS 33c, consensus 30c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PFG

Principal Financial

$65.18

0.87 (1.35%)

16:30
04/27/17
04/27
16:30
04/27/17
16:30
Earnings
Principal Financial reports Q1 ops EPS $1.27, consensus $1.21 »

Reports Q1 assets under…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 16

    May

KTEC

Key Technology

$12.54

-0.54 (-4.13%)

16:29
04/27/17
04/27
16:29
04/27/17
16:29
Hot Stocks
Key Technology wins $9M deal with Lutosa »

Key Technology has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

COLM

Columbia Sportswear

$59.77

0.34 (0.57%)

16:29
04/27/17
04/27
16:29
04/27/17
16:29
Earnings
Columbia Sportswear cuts FY17 operating income to up 3% to $256M-$265M »

Previously forecast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MSCC

Microsemi

$49.14

0.15 (0.31%)

16:29
04/27/17
04/27
16:29
04/27/17
16:29
Earnings
Microsemi sees Q3 non-GAAP EPS 94c-$1.04, consensus 97c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

EHTH

eHealth

$11.74

0.23 (2.00%)

16:29
04/27/17
04/27
16:29
04/27/17
16:29
Earnings
eHealth reports Q1 adjusted EPS $1.93, consensus 39c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

  • 30

    May

  • 06

    Jun

SBUX

Starbucks

$61.28

-0.2792 (-0.45%)

16:28
04/27/17
04/27
16:28
04/27/17
16:28
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks U.S. Rewards…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 24

    May

MSCC

Microsemi

$49.14

0.15 (0.31%)

16:28
04/27/17
04/27
16:28
04/27/17
16:28
Earnings
Microsemi reports Q2 non-GAAP EPS 91c, consensus 89c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

LECO

Lincoln Electric

$89.58

-0.71 (-0.79%)

, AIQUY

Air Liquide

$24.16

-0.23 (-0.94%)

16:28
04/27/17
04/27
16:28
04/27/17
16:28
Hot Stocks
Lincoln Electric acquires acquire Air Liquide welding »

Lincoln Electric Holdings…

LECO

Lincoln Electric

$89.58

-0.71 (-0.79%)

AIQUY

Air Liquide

$24.16

-0.23 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

TCO

Taubman Centers

$64.32

0.02 (0.03%)

16:27
04/27/17
04/27
16:27
04/27/17
16:27
Earnings
Breaking Earnings news story on Taubman Centers »

Taubman Centers backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.